| SEQ_NO | 1 | Date of announcement | 2025/09/24 | Time of announcement | 16:42:51 |
| Subject | Medeon’s Board of Directors resolved to waive participation in PMC’s cash capital increase. | ||||
| Date of events | 2025/09/24 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2025/09/24 2.Company name:Medeon Biodesign, Inc. 3.Relationship to the Company (please enter ‘head office’ or ‘subsidiaries’):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:PMC has entered the commercialization stage. To strengthen its global presence and accelerate strategic collaborations, the Company intends to bring in strategic investors with international resources. In light of the current global capital market uncertainties and in alignment with the Medeon’s overall financial planning, the Board of Directors has resolved to forgo participation in this cash capital increase. 6.Countermeasures: Pursuant to the authorization of PMC’s Board of Directors, the Chairman of PMC is authorized to negotiate with specific parties for the subscription. 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None. |
||||